Welcome to our dedicated page for CERo Therapeutics SEC filings (Ticker: CERO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CERo Therapeutics Holdings, Inc. (CERO) SEC filings page on Stock Titan provides access to the company’s public reports and regulatory disclosures, along with AI-generated summaries to help interpret complex documents. As a clinical-stage biotechnology issuer and emerging growth company, CERo uses SEC filings to describe its immunotherapy platform, clinical programs, capital structure, and risk factors in detail.
Key filings for CERO include current reports on Form 8-K, which the company has used to announce material events such as Nasdaq listing determinations, private placements of Series E convertible preferred stock, equity line of credit agreements with institutional investors, and clinical or corporate presentations furnished under Regulation FD. These 8-Ks often provide timely information on financing terms, changes in trading venue, and progress of the CER-1236 program.
CERo’s registration statements on Form S-1 describe arrangements like its committed equity financing with an institutional investor, including the potential resale of large blocks of common stock issued under common stock purchase agreements. These documents outline how the company may raise capital over time and discuss associated risks and dilution considerations.
Other important disclosures include proxy materials on Schedule 14A, which have covered proposals such as a reverse stock split, increases to the 2024 Equity Incentive Plan share reserve, and approvals related to convertible preferred stock. Notifications like Form 12b-25 (NT 10-Q) explain delays in periodic reporting and provide preliminary financial information when applicable.
On this page, Stock Titan surfaces new CERO filings as they appear in the EDGAR system and applies AI to highlight key sections, such as clinical trial plans, financing covenants, listing status updates, and changes to capital structure. Users can quickly locate 10-K, 10-Q, S-1, 8-K, proxy statements, and other forms, while AI summaries help clarify technical language around preferred stock terms, equity lines, and regulatory or listing developments that may affect CERO shareholders.
Cero Therapeutics Holdings, Inc. granted its Chief Financial Officer, Andrew Kucharchuk, a stock option on January 7, 2026. The option gives the right to buy 1,162,099 shares of common stock at an exercise price of $0.055 per share. The option is listed as exercisable beginning January 7, 2026 and expires on January 6, 2036. Following this grant, Kucharchuk is reported as directly beneficially owning 1,162,099 derivative securities of this type.
CERO Therapeutics Holdings, Inc. has filed a prospectus supplement tied to its Form S-1 registration statement covering 729,596,950 shares of common stock, updating the related prospectus with information from a new Form 8-K.
The Form 8-K notes that the company has released an investor presentation for use in meetings and issued a press release titled “CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion-Free Interval Observed in a Patient with Myelodysplastic Syndrome/AML.” The common stock trades on OTCQB under “CERO” and the public warrants trade on OTCID under “CEROW.”
CERo Therapeutics Holdings, Inc. filed a current report describing new investor and clinical communications. The company furnished an updated corporate presentation as an exhibit, which it plans to use in meetings with investors, analysts and others. This presentation is furnished rather than filed, meaning it is not automatically subject to certain Exchange Act liability provisions.
The company also issued a press release titled “CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion-Free Interval Observed in a Patient with Myelodysplastic Syndrome/AML.” The press release and the presentation are included as exhibits, giving readers access to the latest clinical update and investor materials.
CERO Therapeutics Holdings, Inc. supplements its prospectus covering 729,596,950 shares of common stock by attaching a new current report. The update centers on stockholder approvals from a recent special meeting.
At that meeting, stockholders approved an amendment to the 2024 Equity Incentive Plan to increase the shares of common stock available for issuance, and eligible for incentive stock options, by 32,000,000 shares. As of the November 14, 2025 record date, there were 20,802,671 shares of common stock issued and outstanding and entitled to vote, and 52.82% of those shares were present, satisfying quorum requirements.
The company’s common stock trades on the OTCQB under the symbol “CERO”, and its public warrants trade on OTCID under “CEROW”. On December 19, 2025, the last quoted bid prices were $0.0965 per share of common stock and $0.0005 per warrant.
CERo Therapeutics Holdings, Inc. reported that its stockholders approved an amendment to the company’s 2024 Equity Incentive Plan at a special meeting held on December 19, 2025. The amendment increases the number of shares of common stock available for issuance under the plan, and the number of shares that may be issued pursuant to incentive stock options, by an additional 32,000,000 shares.
At the special meeting, there were 20,802,671 shares of common stock issued and outstanding and entitled to vote as of the record date, and 10,988,347 shares were present in person or by proxy, representing approximately 52.82% of the shares entitled to vote, which constituted a quorum. The company attached the full text of the fourth amendment to the equity incentive plan as an exhibit.
CERo Therapeutics Holdings, Inc. has filed a Form S‑1 to register up to 729,596,950 shares of common stock for potential resale by Keystone Capital Partners under a committed equity financing facility. These shares relate to a series of Common Stock Purchase Agreements through which CERo may, at its discretion, sell stock to Keystone.
The company is not selling securities in this prospectus and will not receive proceeds from Keystone’s resales, though it may receive up to $25 million in aggregate gross proceeds from sales of its stock to Keystone under the Keystone Equity Financing. As of November 24, 2025, CERo had 21,102,671 common shares outstanding, and if all 729,596,950 registered shares were issued and outstanding on a fully diluted basis, they would represent about 80.89% of total common stock.
CERo is a clinical‑stage immunotherapy company developing CER‑1236, an engineered T‑cell therapy that has FDA Orphan Drug and Fast Track designations for acute myeloid leukemia. The company reports recurring losses, substantial doubt about its ability to continue as a going concern, and its common stock now trades on the OTCQB under the symbol CERO following delisting from Nasdaq.
CERo Therapeutics Holdings, Inc. entered a new common stock purchase agreement with an institutional investor that allows the company to sell up to $14,591,939 of its common stock over time, subject to conditions in the agreement. This continues a prior equity line program under which the company previously raised approximately $4.4 million from 11,689 shares, $3.1 million from 100,581 shares, and $2.90 million from 12,500,000 shares of common stock. The company can require the investor to buy shares through fixed purchases, generally capped at the lower of 10,000 shares or $100,000 per transaction, as well as VWAP-based purchases, with an aggregate cap of $10,000,000 per VWAP and related additional VWAP purchases on a given day, so long as the stock price is at least $0.02. The investor’s beneficial ownership is limited to 4.99% of outstanding shares, and a related registration rights agreement provides for registration of shares issued under this arrangement.
CERo Therapeutics Holdings, Inc. has called a virtual special stockholder meeting for December 19, 2025 to vote on several capital and governance actions. Stockholders are asked to approve a reverse stock split of the common stock at a ratio between 1‑for‑40 and 1‑for‑150, with the exact ratio to be chosen by the board, aiming to lift the share price and support a potential relisting on Nasdaq after trading moved to the OTC Pink Sheets.
Investors will also vote on approving the potential issuance of common shares upon conversion of Series E preferred stock issued in an October 2025 private placement under Nasdaq Listing Rule 5635, which could significantly increase the common share count depending on future pricing adjustments. A third proposal would expand the 2024 Equity Incentive Plan by an additional 32,000,000 shares for employee and director awards, and a fourth would allow adjournment of the meeting to gather more votes if needed. The board recommends voting FOR all four proposals.
CERO Therapeutics Holdings, Inc. has an effective registration statement that covers 2,100,000 shares of common stock, and this prospectus supplement simply updates that registration by attaching the company’s latest Quarterly Report on Form 10-Q. The 10-Q shows that CERO, an early-stage immunotherapy developer, is advancing its lead T cell therapy CER-1236 in a Phase 1/1b trial for acute myelogenous leukemia and has a second IND cleared for NSCLC and ovarian cancer.
For the nine months ended September 30, 2025, CERO reported a net loss of $15.4 million, bringing its accumulated deficit to about $86.3 million. Cash, restricted cash and cash equivalents were $2.0 million as of September 30, 2025, while total current liabilities were significantly higher, and the company states there is substantial doubt about its ability to continue as a going concern without additional capital. CERO’s common stock was delisted from Nasdaq after an October 29, 2025 determination and now trades on the OTC Pink Sheets under the symbol CERO; there were 21,102,671 shares outstanding as of November 19, 2025.
CERO Therapeutics Holdings, Inc. is registering 12,500,000 shares of common stock under a supplemented Form S-1, with this prospectus supplement incorporating its latest Quarterly Report on Form 10-Q. The company’s stock now trades on the OTC Pink Sheets under “CERO,” recently quoted at $0.06 per share, with public warrants at $0.009.
The attached 10-Q for the quarter ended September 30, 2025 shows an early-stage immunotherapy business focused on engineered T cell therapies for cancer, including a Phase 1/1b AML trial of lead asset CER-1236, where three patients have been dosed, and a second IND accepted for NSCLC and ovarian cancer. CERO reported a net loss of $15.4 million for the nine months ended September 30, 2025 and an accumulated deficit of $86.3 million, with cash and cash equivalents of about $2.0 million and substantial doubt raised about its ability to continue as a going concern. As of November 19, 2025, 21,102,671 shares of common stock were outstanding.